A multiprovincial retrospective analysis of the incidence of myocarditis or pericarditis after mRNA vaccination compared to the incidence after SARS-CoV-2 infection.

Naveed, Zaeema; Chu, Cherry; Tadrous, Mina; Veroniki, Areti-Angeliki; Li, Julia; Rouleau, Isabelle; Febriani, Yossi; Calzavara, Andrew; Buchan, Sarah A; Nasreen, Sharifa; Schwartz, Kevin L; Wilton, James; Seo, Chi Yon; Thampi, Nisha; Wilson, Sarah E; Naus, Monika; De Serres, Gaston; Janjua, Naveed Z; Kwong, Jeffrey C

Naveed, Zaeema; Chu, Cherry; Tadrous, Mina; Veroniki, Areti-Angeliki; Li, Julia; Rouleau, Isabelle; Febriani, Yossi; Calzavara, Andrew; Buchan, Sarah A; Nasreen, Sharifa; Schwartz, Kevin L; Wilton, James; Seo, Chi Yon; Thampi, Nisha; Wilson, Sarah E; Naus, Monika; De Serres, Gaston; Janjua, Naveed Z; Kwong, Jeffrey C.

Afiliação

Naveed Z; British Columbia Centre for Disease Control, Vancouver, BC, Canada.
Chu C; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
Tadrous M; Women's College Hospital, Toronto, ON, Canada.
Veroniki AA; Women's College Hospital, Toronto, ON, Canada.
Li J; ICES, Toronto, ON, Canada.
Rouleau I; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
Febriani Y; Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
Calzavara A; Institute for Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada.
Buchan SA; British Columbia Centre for Disease Control, Vancouver, BC, Canada.
Nasreen S; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
Schwartz KL; Institut National de Santé Publique Du Québec, Biological Risks Division, Montreal, QC, Canada.
Wilton J; Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, QC, Canada.
Seo CY; ICES, Toronto, ON, Canada.
Thampi N; ICES, Toronto, ON, Canada.
Wilson SE; Public Health Ontario, Toronto, ON, Canada.
Naus M; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
De Serres G; Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, ON, Canada.
Janjua NZ; ICES, Toronto, ON, Canada.
Kwong JC; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Heliyon ; 10(5): e26551, 2024 Mar 15.

Article em En | MEDLINE | ID: mdl-38439866

ABSTRACT

ABSTRACT

Objective:

To compare myocarditis/pericarditis risk after COVID-19 mRNA vaccination versus SARS-CoV-2 infection, and to assess if myocarditis/pericarditis risk varies by vaccine dosing interval.

Methods:

In this retrospective cohort study, we used linked databases in Quebec, Ontario, and British Columbia between January 26, 2020, and September 9, 2021. We included individuals aged 12 or above who received an mRNA vaccine as the second dose or were SARS-CoV-2-positive by RT-PCR. The outcome was hospitalization/emergency department visit for myocarditis/pericarditis within 21 days of exposure. We calculated age- and sex-stratified incidence ratios (IRs) of myocarditis/pericarditis following mRNA vaccination versus SARS-CoV-2 infection. We also calculated myocarditis/pericarditis incidence by vaccine type, homologous/heterologous schedule, and dosing interval. We pooled province-specific estimates using meta-analysis.

Results:

Following 18,860,817 mRNA vaccinations and 860,335 SARS-CoV-2 infections, we observed 686 and 160 myocarditis/pericarditis cases, respectively. Myocarditis/pericarditis incidence was lower after vaccination than infection (IR [BNT162b2/SARS-CoV-2], 0.14; 95%CI, 0.07-0.29; IR [mRNA-1273/SARS-CoV-2], 0.28; 95%CI, 0.20-0.39). Within the vaccinated cohort, myocarditis/pericarditis incidence was lower with longer dosing intervals; IR (56 or more days/15-30 days) was 0.28 (95%CI, 0.19-0.41) for BNT162b2 and 0.26 (95%CI, 0.18-0.38) for mRNA-1273.